---
document_datetime: 2026-02-03 09:48:04
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/galliapharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: galliapharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4191629
conversion_datetime: 2026-02-04 15:12:29.657673
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.12)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## GalliaPharm

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 02/02/2026                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323795                     | PRODUCTS - C.I.z Other variation - Accepted To update SmPC section 12. Instructions for preparation of radiopharmaceuticals by extending the decay factor chart for parent radionuclide germanium-68 (68Ge)by adding values for the period of 53 - 78 weeks after the calibration date. In addition the MAH has taken the opportunity to make minor editorial and grammatical corrections throughout.                                                                                                                     |            |     |             |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA / EMA/VR/0000269727 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 22/05/2025 | N/A |             |
| PSUR / EMA/PSUR/0000282223            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     | Maintenance |